ASH 2023 | Looking to the future in the treatment of beta thalassemia
Maria Domenica Cappellini, MD, University of Milan, Milan, Italy, discusses the treatment landscape of beta thalassemia, focusing on exciting novel treatment options which have the potential to improve outcomes in patients with the disease in the future. This includes the CRISPR/Cas9 genome-editing therapy, which was recently approved for the treatment of sickle cell disease (SCD). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria,: Bristol Myers Squibb, Sanofi, Vertex, Agios
Research Funding: Bristol Myers Squibb, Agios
Board of Directors/Advisory Committee: Sanofi, Vertex
Travel support: Sanofi
Research Funding: Sanofi, Vertex, Silence Therapeutics
